ecancer shared post on LinkedIn:
“At ASCO2026, Dr Menon talks to us about new data from a phase III trial in advanced NSCLC suggesting that lower-dose pembrolizumab may improve outcomes without compromising benefit. Watch now.”
Other articles about ecancer on OncoDaily.